Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024. In the quarter to June 2026, revenue grew 19.6%, EPS grew 65.2%, free cash flow grew 26.7% and total debt rose 2.40%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SGHT
Sight Sciences, Inc. (SGHT) EV/Sales
As of 16 October 2026, Sight Sciences, Inc. (SGHT) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from −0.6× (October 2023) to 19.7× (October 2021); the current reading is higher than 80% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.7× | 262.43% |
| FY2024 | 1.3× | (26.81%) |
| FY2023 | 1.8× | (71.16%) |
| FY2022 | 6.2× | 24.36% |
| FY2021 | 4.9× | (39.77%) |
| FY2020 | 8.2× | 0.00% |
| FY2019 | 8.2× | 0.00% |
| FY2018 | 8.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.1× | 53.95% |
| Mar 2026 | 2.0× | (57.55%) |
| Dec 2025 | 4.7× | 175.12% |
| Sep 2025 | 1.7× | (15.56%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCMD Tactile Systems Technology, Inc. compare | 1.3× |
| CERS Cerus Corporation compare | 1.8× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.6× |
| NPCE NeuroPace, Inc. compare | 4.2× |
| DCTH Delcath Systems, Inc. compare | 4.3× |
| SGHT Sight Sciences, Inc. | 4.9× |
| MASS 908 Devices Inc. compare | 5.6× |
| SENS Senseonics Holdings, Inc. compare | 8.1× |
| SSII SS Innovations International, Inc. compare | 9.6× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)